Advertisement
UK markets close in 4 hours 29 minutes

  • FTSE 100

    8,116.43
    +37.57 (+0.47%)
     

  • FTSE 250

    19,829.69
    +227.71 (+1.16%)
     

  • AIM

    755.53
    +2.41 (+0.32%)
     

  • GBP/EUR

    1.1662
    +0.0006 (+0.05%)
     

  • GBP/USD

    1.2513
    +0.0002 (+0.02%)
     

  • Bitcoin GBP

    51,232.02
    +520.01 (+1.03%)
     

  • CMC Crypto 200

    1,387.13
    -9.40 (-0.67%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CRUDE OIL

    84.11
    +0.54 (+0.65%)
     

  • GOLD FUTURES

    2,360.40
    +17.90 (+0.76%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,050.89
    +133.61 (+0.75%)
     

  • CAC 40

    8,039.12
    +22.47 (+0.28%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of April 30th, 2023

Business Wire
·2-min read

Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF’s General Regulations.

SOPHIA ANTIPOLIS, France, May 10, 2023--(BUSINESS WIRE)--Regulatory News:

Median Technologies (Paris:ALMDT):

Total number of shares

15,801,449

Number of real voting rights*
(excluding treasury shares**)

15,736,196

Theoretical number of voting rights*
(including treasury shares**)

15,778,249

(*) Class E preference shares are non-voting
(**) pursuant to article 223-11 of the AMF’s General Regulations

About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and iBiopsy®, our AI-powered imaging platform for the development of software as medical devices (SaMD), help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.

ADVERTISEMENT

Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label "Innovative company" by the BPI France and is listed on Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information: www.mediantechnologies.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20230510005477/en/

Contacts

Median Technologies
Emmanuelle Leygues
Head of Corporate Marketing & Financial Communications
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com

Press - ALIZE RP
Caroline Carmagnol
+33 6 64 18 99 59
median@alizerp.com

Investors - ACTIFIN
Ghislaine Gasparetto
+33 6 21 10 49 24
ggasparetto@actifin.fr